What's happening
This bill directs the New York health commissioner to study sickle cell treatment disparities and report findings publicly within 18 months.
Why it matters
Focuses on equity in healthcare by requiring the state to specifically investigate whether people with sickle cell disease face more barriers to care compared to those with other chronic diseases like cancer or diabetes.
Could identify concrete gaps in both access to and affordability of treatment for sickle cell patients, potentially informing future policy changes or funding priorities to address these disparities.
Mandates public transparency by requiring that the study’s findings be posted online, empowering patients, advocates, and providers with new data to push for reforms or increased resources.
Creates a time-limited but actionable framework (18 months for the study, two years before repeal), emphasizing urgency and accountability in addressing health inequities.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
People with sickle cell disease
The study would examine whether their treatment is less accessible or affordable than treatment for people with other chronic illnesses.
New York State Department of Health
The commissioner would be required to conduct the study and publish its results on the department’s open health data website within 18 months of the bill’s effective date.
People with lupus, cancer, diabetes or heart disease
Treatment accessibility and affordability for these conditions would serve as comparisons in the sickle cell disparity study.
Headline styles
Study Sickle Cell Treatment Gaps
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8921
IN SENATE
March 28, 2024
Introduced by Sen. PARKER -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT in relation to directing the commissioner of health to conduct a sickle cell disparity study; and providing for the repeal of such provisions upon expiration thereof
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. 1. The commissioner of health is authorized and directed to conduct a sickle cell disparity study.
2. Such study shall determine whether there is a disparity between treatment accessibility and affordability for persons with sickle cell disease and persons with other chronic illnesses, including but not limited to lupus, cancer, diabetes, and heart disease.
3. Not later than eighteen months after the effective date of this act, the commissioner shall post the results of such study on the open health data section of the department of health's website.
§ 2. This act shall take effect immediately and shall expire and be deemed repealed two years after such effective date.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14371-01-4
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act in relation to directing the commissioner of health to conduct a sickle cell disparity study; and providing for the repeal of such provisions upon expiration thereof
Purpose or general idea of bill
This legislation authorizes and directs the commissioner of health to conduct a sickle cell disparity study to determine whether there is a disparity between treatment accessibility and affordability for persons with sickle cell disease and persons with other chronic illnesses.
Summary of specific provisions
Section one authorizes and directs the commissioner of health to conduct a sickle cell disparity study.
Section two provides the effective date and repealer.
Justification
Sickle cell disease (SCD) is a genetic disorder with significant public health implications. Many people, including healthcare professionals, may lack awareness about SCD, leading to delayed diagnosis and inade- quate and inequitable care. The chronic pain episodes (crises) that sickle cell patients often experience are often inadequately addressed or stigmatized, leading to undertreatment. Sickle cell disease histor- ically receives less research funding compared to other genetic disor- ders, and possibly other chronic illnesses, limiting the development of new treatments and therapies.
A statewide sickle cell disparity study can identify and address poten- tial disparities in healthcare access, ensuring that individuals with SCD receive equitable treatment compared to those with other chronic illnesses. This promotes health equity and fairness in healthcare provision. Sickle cell disease has unique medical requirements, includ- ing pain management, regular monitoring, and specialized care. Under- standing if there are disparities can lead to tailored interventions to meet the specific needs of this patient population.
This study may reveal if individuals with SCD are being underdiagnosed or undertreated compared to those with other chronic illnesses, shedding light on gaps in the healthcare system. Sickle cell disease often requires ongoing medical care and can impose a significant financial burden on individuals and their families. Assessing affordability can highlight economic challenges and inform policies to alleviate financial strain. Disparities in accessibility and affordability may contribute to variations in health outcomes.
Understanding these disparities can lead to interventions aimed at improving health outcomes for individuals with SCD. The findings of the study can inform the development of legislation and policies that address disparities and ensure that individuals with SCD have equal access to affordable and effective healthcare.
The study can serve as a basis for community engagement and advocacy efforts. It empowers affected communities to raise awareness about the unique challenges they face and advocate for necessary changes in healthcare policies and practices. Understanding treatment accessibility and affordability disparities can drive research initiatives and inno- vations to improve care delivery models, reduce costs, and enhance over- all healthcare quality for individuals with SCD.
It is ethically imperative to ensure that all individuals, regardless of their health condition, have equal access to healthcare. Conducting a disparity study aligns with the principles of justice and fairness in healthcare provision. This study promotes health equity, addresses unique healthcare needs, identifies potential gaps in diagnosis and treatment, alleviates financial burdens, improves health outcomes, informs legal and policy decisions, engages communities, drives research and innovation, and upholds ethical principles in healthcare.
Prior legislative history
New Bill.
Fiscal implications
EFFECTIVE DATE: This act shall take effect immediately and shall expire and be deemed repealed two years after such effective date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.